Welcome to our dedicated page for Immuneering SEC filings (Ticker: IMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Immuneering Corporation’s (Nasdaq: IMRX) SEC filings, offering a detailed view of how the clinical-stage oncology company reports its operations, financings, and key developments. Immuneering’s Class A common stock is listed on The Nasdaq Global Market, and its Exchange Act reports and current reports on Form 8‑K document material events and corporate actions related to its Deep Cyclic Inhibitor programs.
Through Forms 10‑K and 10‑Q, investors can review Immuneering’s descriptions of its business, risk factors, research and development activities, and financial condition. Current reports on Form 8‑K capture specific events such as underwritten public offerings of Class A common stock, private placements with institutional investors, entry into material definitive agreements, and announcements of clinical data from the atebimetinib program. For example, recent 8‑K filings describe the company’s securities purchase agreement with a Sanofi subsidiary, the terms of a public offering, and updated interim data from a Phase 2a trial of atebimetinib plus modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer.
On Stock Titan, these filings are updated in near real time as they appear on EDGAR and are paired with AI-powered summaries that highlight the most important points. Long, technical documents are distilled to explain how financings affect Immuneering’s cash runway, what new clinical or regulatory milestones are disclosed, and how agreements such as equity distribution arrangements or clinical collaborations fit into the company’s strategy. Users can also track sections that discuss patent protection for atebimetinib, including the U.S. composition of matter patent, and references to planned pivotal Phase 3 trials and combination studies in non-small cell lung cancer.
In addition, this page allows investors to quickly locate any insider transaction reports on Form 4, proxy statements on Schedule 14A, and registration statements or prospectus supplements related to securities offerings, when available. By combining structured access to Immuneering’s filings with AI explanations, the platform helps readers understand how regulatory disclosures relate to the company’s Deep Cyclic Inhibitor pipeline, clinical development plans, and capital structure without having to parse every page manually.
HBM Healthcare Investments (Cayman) Ltd. filed a Schedule 13G reporting beneficial ownership of 3,646,304 shares of Immuneering Corp Class A common stock, representing approximately 5.7% of the 63,483,397 shares outstanding as of September 30, 2025. The filing states the shares were not acquired to change or influence control of the company and that voting and investment power is exercised by HBM's board.
The reporting person is organized in the Cayman Islands and lists sole voting and dispositive power over all reported shares. The statement includes a signature by Jean-Marc LeSieur, Managing Director, dated 10/03/2025.
Insider purchase reported: Immuneering Corp (IMRX) Chief Accounting Officer Mallory Morales reported acquiring 300 shares of Class A common stock on 10/01/2025 at a price of $6.39 per share. After the transaction, Morales beneficially owns 27,533 shares. The Form 4 was signed by an attorney-in-fact on 10/02/2025. No derivative transactions or additional remarks were reported in the filing.
Insider transaction reported for Immuneering Corp (IMRX). Leah R. Neufeld, listed as Chief People Officer and reporting person, purchased 800 shares of Class A common stock on 10/01/2025 at a price of $6.3792 per share. After the purchase, the filing reports 23,344 shares beneficially owned. The Form 4 was signed on behalf of Ms. Neufeld by an attorney-in-fact and dated 10/02/2025.
Immuneering Corp (IMRX) Chief Legal Officer and Secretary Michael D. Bookman reported a personal purchase of 1,020 shares of Class A common stock on 10/01/2025 at a price of $6.8299 per share. Following the transaction, Mr. Bookman beneficially owns 4,870 shares. The Form 4 was signed on 10/02/2025 and lists his role as an officer and director. No derivative transactions or additional remarks were reported on the filing.
Insider purchase reported by Immuneering Corp (IMRX) Peter Feinberg, identified as a Director, reported purchasing 7,500 shares of Class A Common Stock on 09/30/2025 at a weighted-average price of $7.0307 per share. After the purchase Feinberg directly beneficially owned 149,266 shares and also reported indirect holdings of 392,242 shares via PF Associates L.P., 476,615 shares via PEF LLC, and 115,441 shares via S4K Investments LLC. The filing notes the purchase was executed in multiple trades at prices from $7.0049 to $7.055. The Form 4 is signed by an attorney-in-fact on 10/01/2025.
Peter Feinberg, a director of Immuneering Corp (IMRX), reported a purchase of 5,000 Class A common shares on 09/29/2025 at a price of $7.18 per share. After the transaction he beneficially owns 141,766 shares directly, plus additional indirect holdings through entities (392,242; 476,615; 115,441), as listed on the Form 4. The filing was signed by an attorney-in-fact on 09/30/2025. This Form 4 discloses an insider purchase that increases the reporting person’s stake but contains no other financial metrics or commentary.
Immuneering Corporation (IMRX) is offering 18,959,914 shares of Class A common stock at $9.23 per share, with underwriters able to purchase up to 2,843,987 additional shares. Net proceeds from the offering and a contingent concurrent private placement with Aventis Inc., a Sanofi subsidiary, are estimated at approximately $187.4 million (about $212.0 million if the underwriters exercise their option). The company reported updated interim Phase 1/2a atebimetinib data: in 34 first-line pancreatic cancer patients dosed at 320 mg once daily with mGnP, 86% overall survival and 53% progression-free survival at nine months (median PFS 9.6 months; median OS not reached) with a median follow-up of nine months; Grade ≥3 treatment-emergent adverse events included anemia in 24% and neutropenia in 18% of patients and no Grade 5 TEAEs. Proceeds are intended to advance development and are projected to fund operations into 2029 based on current plans. The private placement of up to $25.0 million is contingent on a qualified public offering of at least $75.0 million and includes customary ownership limits and lock-up/standstill provisions.
Immuneering Corporation (IMRX) is offering shares of its Class A common stock and pre-funded warrants, with a concurrent private placement with Aventis Inc., a wholly owned subsidiary of Sanofi, to purchase up to $25.0 million of stock contingent on a firm-commitment public offering that raises at least $75.0 million.
Clinical update: in a 320 mg once-daily atebimetinib plus modified gemcitabine/nab-paclitaxel cohort (N=34, cutoff August 26, 2025), Immuneering reported 86% overall survival and 53% progression-free survival at nine months, median PFS 9.6 months, median OS not reached; six-month rates were 94% OS and 70% PFS. Grade ≥3 TEAEs ≥10% included anemia (24%) and neutropenia (18%); no Grade 5 TEAEs reported.
The company’s Class A common stock trades on Nasdaq under IMRX (last reported sale $8.59 on September 23, 2025). Underwriters will receive a 6.0% commission and an option to purchase additional shares. The private placement shares will not be registered and are expected to close concurrent with the qualified public offering.
Immuneering Corp (IMRX) reported safety and clinical development plans for atebimetinib in an 8-K filed September 24, 2025. In the 320 mg ITT population, treatment-emergent adverse events (TEAEs) occurring in <10% of patients included fatigue (6%), vomiting (3%), febrile neutropenia (3%), hypokalemia (3%) and nausea (3%). No Grade 5 TEAEs or new safety signals were identified.
The company expects regulatory feedback on pivotal Phase 3 trial plans in Q4 2025 and plans to announce updated overall survival (OS) and progression-free survival (PFS) data from 34 first-line pancreatic cancer patients treated with atebimetinib plus mGnP, including presentation at a 2026 scientific conference. Subject to regulatory feedback, Immuneering aims to initiate a pivotal Phase 3 trial by end-2025 and dose the first patient by mid-2026, and may add additional combination arms in 2026, including non-small cell lung cancer.
FAQ
What is the current stock price of Immuneering (IMRX)?
What is the market cap of Immuneering (IMRX)?
